That company had been built around drugs targeting LAG-3 and was associated with Frédéric Triebel, an immunologist generally regarded as a leading authority on LAG-3.
[2] GSK licensed the rights to develop anti-LAG-3 antibodies for autoimmune disease from Immutep in December 2010 in a total deal package worth £64 million.
[4] Prima BioMed, the biotech company which acquired Immutep in 2014, announced a 'single digit' million dollar milestone related to GSK2831781's commencement of the Phase I in January 2015.
[6] In February 2011 the Nantes group and Triebel presented evidence, this time online in Clinical and Experimental Immunology (May 2011 in print), that a single injection of IMP731 can prevent, for many months, Th1-driven skin inflammation in the tuberculin-induced DTH model in primates.
[8] The contract research organization working with GSK is PAREXEL, which will conduct the study at its site at Northwick Park Hospital in London.